Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

By I. Garcia-Murillas, G. Schiavon, B. Weigelt, C. Ng, S. Hrebien, R. Cutts, M. Cheang, P. Osin, A. Nerurkar, I. Kozarewa and 5 more. Science Translational Medicine, 2015

1,077 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2fbc86127f2de8e2f10625503a5b7a4f0ac7ad2b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Pathology and Forensic Medicine

In Pulmonary and Respiratory Medicine

Citations in the corpus

Origins, structures, and functions of circulating DNA in oncology (2016, background): “[236] showed that quantitative mutation tracking in serial samples increased sensitivity for the prediction of relapse in early breast cancer suggesting an application of cirDNA in the surveillance of the recurrence and detection of the minimal residual disease.”
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations (2018, background): “Liquid biopsies are being used to detect both drug-sensitizing and drug-resistance mutations 134 , low-level MRD after surgery 135,136 and to follow the response to treatment 137 .”
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016, positive): “Digital PCR was performed as described previously (18, 19).”
Liquid Biopsy: From Discovery to Clinical Application. (2021, methodology): “C. Alix-Panabières and K. Pantel received funding from the European IMI research project CANCER-ID (115749-CANCER-ID), European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 765492, and ERA-NET EU/TRANSCAN 2 JTC 2016 PROLIPSY.”
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling (2017, background): “Circulating tumor DNA (ctDNA) has been shown to identify MRD shortly after completion of local therapy in patients with non-metastatic breast and colon cancers using assays that require personalization (7,8).”
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer (2016, background): “The possibility that ctDNA could be used to detect micrometastatic disease in patients undergoing surgery with curative intent was suggested in an initial series of 18 patients with advanced colorectal cancer undergoing metastasectomy (29) and also more recently in other solid malignancies such as b”